Source disclosure: February 12, 2026
Fuso Pharmaceutical Industries,Ltd. [4538.T]
TOKYO, Feb 18 (Pulse News Wire) – Fuso Pharmaceutical Industries,Ltd. (4538.T) reported consolidated results for Q3 FY2026 (ending March 2026).
3 billion (+3.4% YoY). 37 billion (-34.8%). net profit attributable to shareholders was ¥1.68 billion (-29.9%).
4 billion with an equity ratio of 38.7%. For the next fiscal year, the company forecasts 5 billion (+1.5%).
Note: Financial figures from the earnings presentation have been removed pending correction. For accurate figures, refer to the company's earnings summary (kessan tanshin) filed separately on TDNet.
AI-translated content. 🟢 Confidence: High See terms •Financial results — FY2026/3 (consolidated)
| Metric | Current | YoY |
|---|---|---|
| Revenue | ¥48,265M | +3.4% |
| Operating profit | ¥2,367M | -34.8% |
| Net profit | ¥1,684M | -29.9% |
Next period forecast
Revenue
¥61,500M
+1.5%Op. profit
¥3,400M
-17.7%Net profit
¥2,300M
+269.2%Source: TDNet filing · Figures in millions of yen